GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » FCF Margin %

Infant Bacterial Therapeutics AB (STU:9IB) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Infant Bacterial Therapeutics AB's Free Cash Flow for the three months ended in Sep. 2024 was €-4.46 Mil. Infant Bacterial Therapeutics AB's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Infant Bacterial Therapeutics AB's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Infant Bacterial Therapeutics AB's current FCF Yield % is -25.02%.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's FCF Margin % or its related term are showing as below:


During the past 10 years, the highest FCF Margin % of Infant Bacterial Therapeutics AB was -14627.31%. The lowest was -24535.80%. And the median was -19581.56%.

STU:9IB's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -135.76
* Ranked among companies with meaningful FCF Margin % only.

Infant Bacterial Therapeutics AB FCF Margin % Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB FCF Margin % Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Infant Bacterial Therapeutics AB's FCF Margin %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's FCF Margin % falls into.


Infant Bacterial Therapeutics AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Infant Bacterial Therapeutics AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-9.049/0
= %

Infant Bacterial Therapeutics AB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-4.457/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » FCF Margin %
Comparable Companies
OSTO:ABLI OSTO:MAGLE XSAT:HAMLET B OSTO:IRLAB A OSTO:SANION OSTO:FLUO OSTO:SYNACT OSTO:CANTA OSTO:IMMU OSTO:INIT VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IBT B:Sweden
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines